A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia

This study is testing CD33-targeted CAR-T cell therapy — a treatment that uses genetically modified immune cells to attack leukemia — in patients with relapsed or treatment-resistant acute myeloid leukemia (AML) whose cancer cells carry the CD33 protein. **You may be eligible if...** - You are 18 or older - You have AML that has relapsed or not responded to standard treatment - Your cancer cells test positive for the CD33 protein (>80% expression) - You meet the Chinese diagnostic criteria for relapsed/refractory AML - Your doctors can prepare CAR-T cells from your own immune cells, OR standard cell preparation has failed and donor cells are being considered **You may NOT be eligible if...** - Your AML does not express CD33 - There are effective standard treatment options still available for you - You have other conditions making the therapy unsafe Talk to your doctor to see if this trial is right for you.